The laser-induced choroidal neovascularization (CNV) mouse model is widely used in neovascular age-related macular degeneration (AMD) research. Developed originally in primates, 1 this model was later adapted to rodents 2 and has been successful in predicting the therapeutic value of anti-VEGF therapies, 3 now approved for treating wet AMD. Yet the reliability of this model in producing consistent CNV lesions is debatable, complicated by many factors: differences in laser parameters and operators, rodent age, sex, background, and lesion analytic methods, as well as variations in inclusion and exclusion criteria-all of which together may impact CNV development or accurate measurement of CNV lesions.
